GSA Capital Partners’s Iterum Therapeutics ITRM Stock Holding History

GSA Capital Partners’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20,312	Closed	-$61K	–	1694
2022 Q2	$61K	Buy	+20,312	New	+$76K	0.01%	1270

Other funds holding ITRM

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.11B AUM 20.67% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GSA Capital Partners's ITRM Position: Q3 2022 in Review

GSA Capital Partners sold out of Iterum Therapeutics (ITRM) in Q3 2022, closing a stake of 20,312 shares — an estimated $61K sold.

GSA Capital Partners first reported a position in ITRM in Q2 2022 and held it in 1 quarter. The position peaked at $61K in Q2 2022. 25 funds tracked by Wall St. Rank hold ITRM as of Q3 2022.

GSA Capital Partners reported no remaining Iterum Therapeutics position as of Q3 2022 after selling out during the quarter.
GSA Capital Partners sold 20,312 Iterum Therapeutics shares in Q3 2022, an estimated $61K.
GSA Capital Partners first reported a position in Iterum Therapeutics in Q2 2022 and held it in 1 quarter.
GSA Capital Partners's Iterum Therapeutics position peaked at $61K in Q2 2022.
25 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2022.

Based on GSA Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.